HY-0102

DRUG3 trials

Sponsors

Shanghai HyaMab Biotech Co.,Ltd., Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions

Advanced Solid TumorLocally Advanced/Metastatic Solid TumorsMetastatic Pancreatic Cancer

Phase 1

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

CompletedNCT04914351

Shanghai HyaMab Biotech Co.,Ltd.Locally Advanced/Metastatic Solid Tumors

Start: 2022-05-03End: 2023-12-30Updated: 2024-03-13

A Study of HY-0102 in Patients With Advanced Solid Tumors

Shanghai YingLi Pharmaceutical Co. Ltd.Advanced Solid Tumor

Start: 2023-12-18End: 2025-12-31Target: 50Updated: 2024-06-13

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not yet recruitingNCT06662669

Shanghai YingLi Pharmaceutical Co. Ltd.Metastatic Pancreatic Cancer

Start: 2024-11-30End: 2028-08-30Target: 120Updated: 2024-10-29